Thromb Haemost 2005; 94(05): 901-906
DOI: 10.1160/TH05-06-0407
Review Article
Schattauer GmbH

Potential predictors of bleeding risk in inherited factorVII deficiency

Clinical, biological and molecular criteria
Muriel Giansily-Blaizot
1   University Hospital, Laboratory of Hematology, Montpellier, France
,
Jean-Francois Schved
1   University Hospital, Laboratory of Hematology, Montpellier, France
› Author Affiliations
Further Information

Publication History

Received: 10 June 2005

Accepted after revision: 09 September 2005

Publication Date:
14 December 2017 (online)

Summary

Due to the wide molecular and clinical heterogeneities of inherited factor VII (FVII) deficiency, consensus guidelines for management of this coagulation disorder are not currently well established. Therefore, potential clinical, plasmatic or genetic criteria, that could be predictive for bleeding tendency in this condition, have been evaluated. Genotypic criteria including FVII genotypes and thrombophilic mutations are of particular interest to better understand some of the variations observed in bleeding phenotypes but they are still poorly informative for the management of surgery in FVII-deficient patients. Up to now, no plasma parameters have been found to be reliable predictors of bleeding risk. Nevertheless, tissue factor and platelet pathways remain to be explored. Finally, clinical history appears to be the best predictor of bleeding risk after haemostatic challenges in inherited FVII deficiencies. Furthermore, the absence of history of bleeding or mild bleeding phenotypes including menorrhagia, bruises and epistaxis (not inducing iron deficiency anaemia or requiring blood substitutive treatment) could enable minor surgery to be performed in FVII-deficient patients without blood replacement therapy.

 
  • References

  • 1 Cooper DN, Millar DS, Wacey A. et al. Inherited factor VII deficiency: molecular genetics and pathophysiology. Thromb Haemost 1997; 78: 151-60.
  • 2 Perry DJ. Factor VII deficiency. Br J Haematol 2002; 118: 689-700.
  • 3 Triplett DA, Brandt JT, McGann Batard MA. et al. Hereditary Factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis. Blood 1985; 66: 1284-7.
  • 4 Yorke AJ, Mant MJ. Factor VII deficiency and surgery. Is preoperative replacement therapy necessary?. J Am Med Assoc 1977; 238: 424-5.
  • 5 Mariani G, Mazzucconi MG. Factor VII congenital deficiency. Clinical picture and classification of the variants. Haemostasis 1983; 13: 169-77.
  • 6 Peyvandi F, Mannucci PM, Asti D. et al. Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency. Haemophilia 1997; 3: 242-6.
  • 7 Giansily-Blaizot M, Biron-Andréani C, Aguilar-Martinez P. et al. Inherited factor VII deficiency and surgery: clinical data are the best criteria to predict the risk of bleeding. Br J Haematol 2002; 117: 172-5.
  • 8 Edgington TS, Mackman N, Brand K. et al. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
  • 9 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance and regulation. Biochemistry 1991; 30: 10363-70.
  • 10 Butenas S, Van’t Veer C, Mann KG. “Normal” thrombin generation. Blood 1999; 94: 2169-78.
  • 11 Mariani G, Herrmann FH, Dolce A. et al. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93: 481-7.
  • 12 Ingerslev J, Kristensen L. Clinical picture and treatment strategies in factor VII deficiency. Haemophilia 1998; 4: 689-96.
  • 13 Pawlinski R, Fernandes A, Kehrle B. et al. Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction. Proc Natl Acad Sci U S A 2002; 99: 15333-8.
  • 14 Zimmermann R, Ehlers G, Ehlers W. et al. Congenital factor VII deficient. A report of four new cases. Blut 1979; 38: 119-25.
  • 15 Barnett JM, Demel KC, Mega AE. et al. Lack of bleeding in patients with severe factor VII deficiency. Am J Hematol 2005; 78: 134-7.
  • 16 Cheng JC, Wong RW, Yan BS. Postoperative bleeding with factor VII deficiency: case report. Aust Dent J 1998; 43: 382-4.
  • 17 Wei D C, Wong R, Robertson E P. Congenital factor VII deficiency presenting as delayed bleeding following dental extraction. A review of the role of Factor VII in coagulation. Pathology 1997; 29: 234-7.
  • 18 O’Brien DP, Gale KM, Anderson JS. et al. Purification and characterization of factor 304Gln: a variant molecule with reduced activity isolated from a clinically unaffected male. Blood 1991; 78: 132-40.
  • 19 Girolami A, Fabris F, Dal Bo Zanon R. et al. Factor VII Padua: a congenital coagulation disorder due to an abnormal factor VII with a peculiar activation pattern. J Lab Clin Med 1978; 91: 387-95.
  • 20 Zheng DQ, Shurafa M, James HL. Factor VII G331D: a variant molecule involving replacement of a residue in the substrate-binding region of the catalytic domain. Blood Coagul Fibrinolysis 1996; 7: 93-6.
  • 21 Giansily-Blaizot M, Verdier R, Biron-Adréani C. et al. Analysis of biological phenotypes from 42 patients with inherited FVII deficiency: can biological tests predict the bleeding risk?. Haematologica 2004; 89: 704-9.
  • 22 Al Dieri R, Peyvandi F, Santagostino E. et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002; 88: 576-82.
  • 23 Giansily-Blaizot M, Al Dieri R, Schved JF. Thrombin generation measurement in factor VII-depleted plasmas compared to inherited factor VII-deficient plasmas. Pathophysiol Haemost Thromb 2003; 33: 36-42.
  • 24 Broze Jr GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-46.
  • 25 Bolton-Maggs PH, Perry DJ, Chalmers EA. et al. The rare coagulation disorders review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia 2004; 10: 593-628.
  • 26 Lawson JH, Kalafatis M, Stram S. et al. A model for the tissue factor pathway to thrombin. An empirical study. J Biol Chem 1994; 269: 23357-66.
  • 27 Mac Vey J, Boswell E, Mumford AD. et al. Factor VII deficiency and the FVII mutation database. Hum Mutat 2001; 17: 3-17.
  • 28 Chaing S, Clarke B, Sridhara S. et al. Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor. Blood 1994; 83: 3524-35.
  • 29 Arbini AA, Pollak ES, Bayleran JK. et al. Severe factor VII deficiency due to a mutation disrupting a hepatocyte nuclear factor 4 binding site in factor VII promoter. Blood 1997; 89: 176-82.
  • 30 Mc Vey JH, Boswell EJ, Takamiya O. et al. Exclusion of the first EGF domain of factor VII by a splice site mutation causes lethal factor VII deficiency. Blood 1998; 92: 920-6.
  • 31 Tamary H, Fromovich-Amit Y, Shalmon L. et al. Molecular characterization of four novel mutations causing factor VII deficiency. Hematol J 2000; 1: 382-9.
  • 32 Herrmann FH, Wulff K, Auberger K. et al. Molecular biology and clinical manifestation of hereditary factor VII deficiency. Semin Thromb Hemost 2000; 26: 393-400.
  • 33 Takamiya O, Okimoto Y. Severe factor VII deficiency with recurrent intracranial haemorrhages owing to double heterozygosity for a splice site mutation of an IVS4 and a novel nonsense mutation in exon 8 (Gln211àTerm). Br J Haematol 2001; 114: 369-74.
  • 34 Giansily-Blaizot M, Aguilar-Martinez P, Mazurier C. et al. Prenatal diagnosis of severe factor VII deficiency using mutation detection and linkage analysis. Br J Haematol 2001; 112: 248-53.
  • 35 Borensztajn K, Chafa O, Alhenc-Gelas M. et al. Characterization of two novel splice site mutations in human factor VII gene causing severe plasma factor VII deficiency and bleeding diathesis. Br J Haematol 2002; 117: 168-71.
  • 36 Ariffin H, Millar DS, Cooper DN. et al. Prenatal exclusion of severe factor VII deficiency. J Pediatr Hematol Oncol 2003; 25: 418-20.
  • 37 Giansily-Blaizot M, Aguilar-Martinez P, Briquel ME. et al. Two novel cases of cerebral haemorrhages at the neonatal period associated with inherited factor VII deficiency, one of them revealing a new nonsense mutation (Ser52Stop). Blood Coagul Fibrinolysis 2003; 14: 217-20.
  • 38 Gomez K, Laffan MA, Kemball-Cook G. et al. Two novel mutations in severe factor VII deficiency. Br J Haematol 2004; 126: 105-10.
  • 39 Hewitt J, Ballard JN, Nelson TN. et al. Severe FVII deficiency caused by a new point mutation combined with a previously undetected gene deletion. Br J Haematol 2005; 128: 380-5.
  • 40 Rosen ED, Chan JCY, Idusogie E. et al. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature 1997; 390: 290-3.
  • 41 Peyvandi F, Mannucci PM, Jenkins PV. et al. Homozygous 2bp deletion in the human factor VII gene: a non-lethal mutation that is associated with a complete absence of circulating factor VII. Thromb Haemost 2000; 84: 635-7.
  • 42 Peyvandi F, Jenkins PV, Mannucci PM. et al. Molecular characterisation and three-dimensional structural analysis of mutations in 21 unrelated families with inherited factor VII deficiency. Thromb Haemost 2000; 84: 250-7.
  • 43 Takamiya O, Kemball-Cook G, Martin DM. et al. Detection of missense mutations by single-strand conformational polymorphism (SSCP) analysis in five dysfunctional variants of coagulation factor VII. Hum Mol Genet 1993; 2: 1355-9.
  • 44 Bernardi F, Liney DL, Patracchini P. et al. Molecular defects in CRM+ factor VII deficiencies: modelling of missense mutations in the catalytic domain of FVII. Br J Haematol 1994; 86: 610-8.
  • 45 Bernardi F, Castaman G, Pinotti M. et al. Mutation Pattern in clinically Asymptomatic Coagulation Factor VII Deficiency. Human Mutation 1996; 8: 108-15.
  • 46 Giansily-Blaizot M, Aguilar-Martinez P, Biron-Andreani C. et al. Analysis of the genotypes and phenotypes of 37 unrelated patients with inherited factor VII deficiency. Eur J Hum Genet 2001; 9: 105-12.
  • 47 Fromovich-Amit Y, Zivelin A, Rosenberg N. et al. Characterization of mutations causing factor VII deficiency in 61 unrelated Israeli patients. J Thromb Haemost 2004; 2: 1774-81.
  • 48 James HL, Girolami A, Hubbard JG. et al. The dysfunction of coagulation factor VIIPadua results from substitution of arginine-304 by glutamine. Biochim Biophys Acta 1993; 1172: 301-5.
  • 49 Marchetti G, Patracchini P, Gemmati D. et al. Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene. Hum Genet 1992; 89: 497-502.
  • 50 Hunault M, Arbini AA, Lopaciuk S. et al. The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. Arterioscler Thromb Vasc Biol 1997; 17: 2825-9.
  • 51 Pollak E, Hung HL, Godin W. et al. Functional characterisation of the human factor VII 5’-flanking region. J Biol Chem 1996; 271: 1738-47.
  • 52 Van’t Hooft FM, Silveira A, Tornvall P. et al. Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood 1999; 93: 3434-41.
  • 53 Bernardi F, Marchetti G, Pinotti M. et al. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb Vasc Biol 1996; 16: 72-6.
  • 54 Pinotti M, Toso R, Girelli D. et al. Modulation of factor VII levels by intron 7 polymorphisms: population and in vitro studies. Blood 2000; 95: 3423-8.
  • 55 Carew JA, Basso F, Miller GJ. et al. A functional haplotype in the 5’ flanking region of the factor VII gene is associated with an increased risk of coronary heart disease. J Thromb Haemost 2003; 1: 2179-85.
  • 56 Castoldi E, Govers-Riemslag JW, Pinotti M. et al. Coinheritance of Factor V Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation. Blood 2003; 102: 4014-20.